glp-1 and vision changes Possible Link Between RA Medications & Eye Health US court centralizes vision-loss lawsuits

Studies on meal replacement programs in low-calorie diet contexts consistently show better outcomes for body composition, metabolic markers, and nutrient sufficiency compared to generalized eat less, supplement protein approaches

Setmelanotide, a selective agonist of the MC4R, is approved by the FDA and EMA for the treatment of obesity and control of hunger in Bardet-Biedl Syndrome or biallelic pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency in affected children above age 2 years-old [103]

Interestingly, GLP-1 RAs work better for weight loss in people without diabetes

Diabetic kidney disease (DKD), the clinical manifestation of DN, has an early phase called incipient diabetic nephropathy

The increased risk of ketoacidosis in patients with medium to low C-peptide is a limiting factor to the use of SGLT2is in patients with LADA